Alberto Fernández announced that Argentina will produce the coronavirus vaccine developed by the University of Oxford and which will be ready to be used in the first half of 2021. The cost will be between 3 and 4 dollars.
The President stated that the vaccine cycle is not finished (it is still in phase 3) but stated that the objective is to manufacture between 250 and 350 million doses to be distributed throughout Latin America with the exception of Brazil.
As explained by the president, the vaccine will be manufactured in conjunction with Mexico to be delivered « equitably between the countries that demand it and at the request of the governments of those countries. »
« We want Argentina not to have to wait and can access as quickly as possible, » the head of state began the announcement. And he added: “For us it is a great joy. In Argentina AstraZeneca chose the Masayans laboratory to be the producer of the vaccine reagent, it is a recognition of the quality of Argentine laboratories. Mexico will be in charge of packaging the vaccine and completing the production process ”.
“I want to express my satisfaction for this because it puts Argentina in a place of tranquility, to be able to have the vaccine in a timely manner and in sufficient quantity to cover the demand immediately. I want to place particular emphasis on the work of AstraZeneca, which is of Anglo-Swedish origin that has been in Argentina for many years and made an agreement with Oxford to develop this vaccine, ”he said.
He also warned that the country will access the vaccine « at much more than reasonable prices » and stressed that « this is very important for Latin America because all countries will be able to access it. »
“This is very good news about how the private and public sectors can work. It is great news that Mexico and Argentina are the reference points and that we can bring a solution to the continent and we hope to start the production process as soon as possible ”, he completed.
In turn, the Minister of Health, Ginés González García, expressed his joy at the announcement and explained: “The guaranteed access to the vaccine is that the price is reasonable. We are proud because it is not easy to produce the raw material for a vaccine of this complexity, between the end of the vaccine cycle, which is not finished, but this vaccine is ahead in terms of clinical development. There are publications that say that this vaccine has an extraordinary immunity capacity, 91% with one dose and 100% with two ”.
However, he warned: “It is neither the only negotiation nor perhaps it is the only alternative, A clinical experience is being carried out with another provider in order to make sure which one is the most effective and when we can count on it ”.
In the same way, he stressed that « having the local production capacity is very good news because it provides security of access to the vaccine in a timely manner » and announced that « before the end of the experimental phase studies, production will begin « But that » if the vaccine is not useful, everything that has been invested in production will be lost. »
News in Development